On March 28, 2013, the Board of Directors of Ignyta, Inc. (NASDAQ:RXDX) adopted the Ignyta, Inc. Employment Inducement Incentive Award Plan (the “Inducement Plan”). Ignyta Inc. (NASDAQ:RXDX) shares after opening at $6.97 moved to $7.39 on last trade day and at the end of the day closed at $6.68. Ignyta Inc. (NASDAQ:RXDX) showed a negative weekly performance of -22.24%.
PharmAthene, Inc. (NYSEMKT:PIP) has announced that the company received notice from the HHS or the Department of Health & Human Services, the BARDA or Biomedical Advanced Research & Development Authority, advising them of the decision to de-scope the present SparVax anthrax-vaccine contract via a part termination for convenience. PharmAthene, Inc. (NYSEMKT:PIP) shares fell -3.05% in last trading session and ended the day on $1.59. PIP return on equity ratio is recorded as -111.00% and its return on assets is -55.00%. PharmAthene, Inc. (NYSEMKT:PIP) yearly performance is -4.22%.
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) is a biomedical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well. Five Prime Therapeutics Inc. (NASDAQ:FPRX) shares moved down -0.95% in last trading session and was closed at $16.14, while trading in range of $14.80 – $16.65. Five Prime Therapeutics Inc. (NASDAQ:FPRX) year to date (YTD) performance is -3.87%.
Puma Biotechnology, Inc. (NYSE:PBYI) saw a big move last session, as the company’s shares fell by over 18% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. Puma Biotechnology Inc. (NYSE:PBYI) weekly performance is -28.03%. On last trading day company shares ended up $80.86. Puma Biotechnology Inc. (NYSE:PBYI) distance from 50-day simple moving average (SMA50) is -30.56%. Analysts mean target price for the company is $134.50.